抗体-药物偶联物治疗肝胰胆恶性肿瘤：拯救的“灵丹妙药”？
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: "Magic bullets" to the rescue?
发表日期：2024 Jul 29
作者：
Charalampos Theocharopoulos, Ioannis A Ziogas, Charalampos-Christos Douligeris, Andreas Efstathiou, Epaminondas Kolorizos, Dimitrios C Ziogas, Elissaios Kontis
来源：
CANCER TREATMENT REVIEWS
摘要：
肝胰胆管 (HPB) 恶性肿瘤是一组高度侵袭性的癌症，预后较差。不适合根治性手术切除的患者可采用全身化疗进行治疗，然而，这几乎没有带来生存获益。抗体药物偶联物 (ADC) 是三方化合物，将单克隆抗体复杂的选择性和特异性与所附超毒有效负载的细胞破坏能力相结合。鉴于对提高 HPB 癌症患者生存率的药物的需求尚未得到满足，用于治疗 HPB 恶性肿瘤的 ADC 评估已成为广泛临床和临床前研究的焦点，并显示出令人鼓舞的初步结果。在当前的综述中，我们对针对 HPB 恶性肿瘤进行测试的 ADC 方法的越来越多的证据进行了全面概述。从对 ADC 功能原理的简明讨论开始，我们在此总结了评估 ADC 在 HPB 癌症中的临床前和临床研究的所有可用数据。版权所有 © 2024 Elsevier Ltd。保留所有权利。
Hepato-Pancreato-Biliary (HPB) malignancies constitute a highly aggressive group of cancers that have a dismal prognosis. Patients not amenable to curative intent surgical resection are managed with systemic chemotherapy which, however, confers little survival benefit. Antibody-Drug Conjugates (ADCs) are tripartite compounds that merge the intricate selectivity and specificity of monoclonal antibodies with the cytodestructive potency of attached supertoxic payloads. In view of the unmet need for drugs that will enhance the survival rates of HPB cancer patients, the assessment of ADCs for treating HPB malignancies has become the focus of extensive clinical and preclinical investigation, showing encouraging preliminary results. In the current review, we offer a comprehensive overview of the growing body of evidence on ADC approaches tested for HPB malignancies. Starting from a concise discussion of the functional principles of ADCs, we summarize here all available data from preclinical and clinical studies evaluating ADCs in HPB cancers.Copyright © 2024 Elsevier Ltd. All rights reserved.